Associate Professor David LYE Chien Boon (MBBS, FRACP, FAMS, FRCP) graduated in medicine on the Dean’s List from the University of Melbourne in 1996 and completed specialty training in infectious diseases in Australia in 2004. He returned to Singapore in 2005 and has worked at Communicable Disease Centre, Department of Infectious Diseases, Tan Tock Seng Hospital (TTSH) since 2005.
He is currently senior consultant, Institute of Infectious Diseases and Epidemiology (IIDE), TTSH, and was appointed associate professor at Yong Loo Lin School of Medicine, National University of Singapore in 2014 and at Lee Kong Chian School of Medicine, Nanyang Technological University in 2016. At IIDE, Assoc Prof Lye leads the Training and Education Unit, and at TTSH, he has led the Antimicrobial Stewardship Programme since 2009. He is the current chair of the National Antimicrobial Stewardship Expert Panel.
Other than clinical, educational, research and administrative work, Assoc Prof Lye is active in the Academy of Medicine Singapore and College of Physicians Singapore. In addition, he is the President of Society of Infectious Disease (Singapore) since 2015 and on the executive committee of Action for AIDS (AFA).
Assoc Prof Lye was a co-principal investigator of the STOP-dengue translational clinical research programme (2008-2014), which focused on the control, treatment and prevention of adult dengue. Clinial research highlights from clinical research of the STOP-dengue include a large retrospective cohort of adult dengue from 2005 to 2008 (“ARDENT”) and a prospective adult dengue study (“PADS”) from 2010 to 2012, which have provided a lot of insights into the management of adult dengue, especially among the elderly. A randomised clinical trial of prophylactic platelet transfusion for adult dengue patients with thrombocytopenia (ADEPT) was completed.
As the principal investigator of Singapore Infectious Disease Clinical Research Network (SCRN), Assoc Prof Lye is involved in randomised clinical trials to optimise antibiotic use in the era of antibiotic resistance. A-KLASS is a clinical trial of oral versus intravenous antibiotics to treat Klebsiella liver abscess. MERINO and MERINO-2 are two clinical trials studying carbapenem-sparing therapy for E coli and K pneumoniae bacteraemia with extended spectrum beta-lactamases, and gram-negative bacteraemia with chromosomal AmpC producers respectively, in collaboration with Australasian Society for Infectious Diseases Clinical Research Network (ASID CRN). Funded via Late Phase Clinical Trial Grant, CAMERA-2 is a clinical trial in collaboration with ASID CRN on better ways of treating methicillin-resistant S aureus bacteraemia.
(for full list, see https://www.ncbi.nlm.nih.gov/pubmed/?term=Lye+D%5Bauthor%5D
1. Lye DC, Lee VJ, Sun Y, Leo YS. The lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in acute uncomplicated adult dengue infection. Clin Infect Dis 2009;48:1262-5. (IF 8.19)Lye DC, Lee VJ, Sun Y, Leo YS. The lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in acute uncomplicated adult dengue infection. Clin Infect Dis 2009;48:1262-5. (IF 8.19)
2. DC Lye, A Earnest, ML Ling, TE Lee, HC Yong, DA Fisher, P Krishnan, LY Hsu. Healthcare-associated Gram-negative bacteraemia cohort study – multidrug-resistance increases hospitalisation costs but not mortality. Clin Micro Infect 2012;18:502-8. (IF 4.78)DC Lye, A Earnest, ML Ling, TE Lee, HC Yong, DA Fisher, P Krishnan, LY Hsu. Healthcare-associated Gram-negative bacteraemia cohort study – multidrug-resistance increases hospitalisation costs but not mortality. Clin Micro Infect 2012;18:502-8. (IF 4.78)
3. DR Bowers, YX Liew, DC Lye, AL Kwa, LY Hsu, VH Tam. Outcome of Appropriate Empiric Combination versus Monotherapy for Pseudomonas aeruginosa Bacteremia. Antimicrob Ag Chemother 2013;57:1270-4. (IF=4.57)DR Bowers, YX Liew, DC Lye, AL Kwa, LY Hsu, VH Tam. Outcome of Appropriate Empiric Combination versus Monotherapy for Pseudomonas aeruginosa Bacteremia. Antimicrob Ag Chemother 2013;57:1270-4. (IF=4.57)
4. L Rivino, EAP Kumaran, V Jovanovic, K Nadua, EW Teo, SW Pang, GH Teo, VCH Gan, DC Lye, YS Leo, BJ Hanson, KG Smith, A Bertoletti, MD Kemeny, PA MacAry. CD4+T Cell Epitopes Recognize Antibody Virion Protein Targets in Secondary Dengue Infections. Journal of Virology 2013;87:2693-706. (IF=5.08)
5. TM Ng, CB Teng, DC Lye, A Apisarnthanarak. A multi-center case-case control study for risk factors and outcomes of extensively drug resistant Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2014;35:49-55. (IF=4.020)
6. JG Low, C Sung, L Wijaya, Y Wei, APS Rathore, S Watanabe, BH Tan, YL Toh, LT Chua, Y Hou, A Chow, SQ Howe, WK Chan, KH Tan, JS Chung, BP Cherng, D Lye, PA Tambayah, LC Ng, J Connolly, M Hibberd, YS Leo, YB Cheung, EE Ooi, SG Vasudevan. Efficacy and safety of celgosivir, an alpha-glucosidase inhibitor, in dengue fever patients evaluated in a randomized, double blind, placebo controlled proof-of-concept clincal trial. Lancet Infect Dis 2014;14:706-15. (IF=19.97)
7. Lew KY, Tan M, Tan SH, Lew EL, Ling LM; Ang B, Lye D, Teng C. Safety and clinical outcomes of Carbapenem De-escalation as Part of an Antimicrobial Stewardship Program in an ESBL-endemic Setting. J Antimicrob Chemother 2015;70:1219-25. (IF=5.439)
8. Rivino, EA Kumaran, TT Linn, CT Too, VCH Gan, BJ Hanson, A Wilder-Smith, A Bertoletti, NRJ Gascoigne, DC Lye, YS Leo, AN Akbar, DM Kemeny, PA MacAry. Virus-specific T lymphocytes home to the skin during natural dengue infection. Sc Transl Med 2015;7: 278ra35. (IF=14.41)
9. TL Thein, J Wong, YS Leo, EE Ooi, D Lye, TW Yeo. Increase Vascular Nitric Oxide Bioavailability is Associated with Progression to Dengue Hemorrhagic Fever in Adults. Journal Infectious Diseases 2015;212:711-4. (IF=5.78)
10. P Tan, DC Lye, TK Yeo, CY Cheung, TL Thein, JG Wong, R Agrawal, LJ Li, TY Wong, VC Gan, YS Leo, SC Teoh. A prospective case-control study to investigate retinal microvascular changes in acute dengue infection. Scientific Reports 2015;5:17183. (IF=5.578)